Navigation Links
Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
Date:4/20/2012

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and University of Kentucky have found that breast cancer survivors who have had chemotherapy, radiation or both do not perform as well on some cognitive tests as women who have not had cancer.

They published their study in the April 1 issue of Cancer.

"Survivors of breast cancer are living longer, so there is a need to better understand the long-term effects of cancer therapies, such as chemotherapy and radiation," said study lead author Paul B. Jacobsen, Ph.D., associate center director for Population Sciences.

To carry out their study, the researchers recruited 313 women being treated by either chemotherapy or radiotherapy for early stage breast cancer at Moffitt Cancer Center and the University of Kentucky Chandler Medical Center. Those who had undergone treatment for cancer were tested six months after treatment and then tested again 36 months after having completed treatment.

They also recruited a control group of women who did not have cancer. These participants were also tested at six months and 36 months.

Participants in all groups were within five years of age, and breast cancer patients were matched with noncancer patients who lived in their same ZIP codes. Participants were tested cognitively with respect to processing speed (quick task completion under pressure), executive functioning (ability to shift cognitive sets and solve novel problems), the two domains expected to be most affected by chemotherapy. They were also tested with regard to verbal abilities.

"Our findings were partially consistent with prior research," explained Jacobsen. "We found that chemotherapy-treated patients performed worse than noncancer controls in processing speed, executive functioning and verbal ability. These domains may be the domains most affected by chemotherapy."

The also found test results for the radiotherapy group to be similar to the results of those in the chemotherapy group. Additionally, they discovered that the noncancer group improved in these cognitive abilities over time while the chemotherapy and radiotherapy groups did not. There were no differences in performance between the radiotherapy and chemotherapy groups, noted the researchers.

The researchers commented that they were fortunate for having included the radiotherapy groups because their results were so similar to the chemotherapy group. Had that group not been included, conclusions could have been drawn to suggest that the cognitive differences between the noncancer group and the chemotherapy group were specific to chemotherapy.

"Since patients report cognitive problems that interfere with their daily activities, early workups should include tests to determine cognitive functioning prior to treatment," concluded Jacobsen. "Future research also needs to investigate factors that may affect both chemotherapy patients and those receiving radiotherapy. Providers may wish to communicate that such effects can accompany chemotherapy and radiation therapy."


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. New Moffitt Cancer Center patent promises to accelerate cancer trials
2. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
3. Fibroblasts contribute to melanoma tumor growth, say Moffitt Cancer Center researchers
4. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
5. Moffitt researchers will be strong participants in American Society of Hematology meeting
6. Moffitt Cancer Center researchers find MK1775 active against sarcomas
7. Moffitt Cancer Center researchers find men less willing to be screened for cancer
8. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
9. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
10. Moffitt Cancer Center researchers find more clues to causes of breast cancer
11. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... ... ... A stressful work environment can hurt the physical and emotional health of employees. ... workplace. The goal of Clearview Resolution Services has always been to help others, starting ... will be shutting down the office early on Fridays. The Clearview team will use ...
(Date:4/25/2017)... Lutz, FL (PRWEB) , ... April 25, 2017 , ... ... transform their smiles by using Invisalign® in Lutz, FL. With the help ... oral health and aesthetics with fewer potential complications, more discretion and less pain. ...
(Date:4/25/2017)... ... ... Back Pain Centers of America (BPC), which connects people searching ... area, announces the launch of a new and proprietary customer relationship management (CRM) system ... physicians to help them with back or neck pain and helps to match them ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Emergency Physician ... book of the Outlier Leadership Series, Outliers in Writing, set to publish in summer ... of Emergency Medicine at the University of Arizona College of Medicine. He also serves ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... YORK , April 19, 2017 The Mobile ... to showcase a healthy CAGR during the forecast period ... type in the global digital mobile X-Ray devices market, which ... Mn in 2017, expanding at a CAGR of 7% over ... absolute $ opportunity of more than US$ 100 Mn in ...
Breaking Medicine Technology: